Make Your First AppointmentGet a Second Opinion
Call us: 877-442-3324
The Gynecologic Oncology Program at the Susan F. Smith Center for Women's Cancers at Dana-Farber is committed to providing expert, compassionate care for patients with gynecologic cancers, including cervical cancer, endometrial/uterine cancer, gestational trophoblastic disease, ovarian cancer, vaginal cancer and vulvar cancer. Because gynecologic cancers can have a wide range of physical and emotional effects, we offer multi-dimensional services to strengthen mind, body, and soul for our patients and their families. You are not alone in this journey.
Donna GregoryCancer patient
As a major research institution, Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) is able to provide patients not only with outstanding care, but also with some of the most advanced therapies available.
We base our treatments on the latest scientific findings, and many patients have the opportunity to participate in clinical trials of promising new treatments. See current open trials for patients with:
Ovarian cancer: Newly diagnosed and recurrent; peritoneal cancer, or fallopian tube cancer
Cervical cancer: Advanced or recurrent
Endometrial (uterine) cancer
Gestational trophoblastic disease
Researchers in the Gynecologic Oncology Program are exploring gynecologic cancers from a wide variety of scientific angles – from discoveries about the genes that cause tumors to develop and grow, to investigations of new therapies, to studies of ways to prevent cancers from forming.
Our physician-scientists are focused on the development of new treatments for specific subtypes of gynecologic cancers, including PARP inhibitors for BRCA-related high grade serous ovarian cancer. They are also delving deep into the genetic underpinnings of gynecologic cancers to find the mutations responsible for the disease.
Read more about recent DF/BWCC research findings, based on cancer type:
Combination therapy for ovarian cancer delivers a double punch.
Researchers look for new ways to treat cancers caused by the HER2 and HER3 proteins.
Testing a new generation of targeted therapies for breast and gynecologic cancers.
Researchers at Dana-Farber look at the ways certain breast and ovarian cancers have similar gene mutations and shared treatments.
Tissue samples donated by patients are among medical researchers' most precious resources.
A young woman benefits from advanced radiation therapy for invasive cervical cancer.
Using the powerful tools of genomic research, Alexi Wright, MD, has begun probing the relatively unknown cellular territory of cervical cancer, hunting for new opportunities to block the mutated gene pathways driving the cancer.
Using human tissue samples has helped researchers develop effective treatments for many breast and gynecologic cancers.
Scientists find pathways that control cell growth in endometrial and cervical cancer.
Tarceva, a targeted therapy used to treat some types of non-small cell lung cancers, is showing promise in treating vulvar cancer in a recent Dana-Farber clinical trial.
Research by Ursula Matulonis, MD
Research by Joyce Liu, MD, MPH
Research by Panos Konstantinopoulos, MD, PhD
Research by Alexi Wright, MD, MPH
Research by Susana Campos, MD, MPH
Research by Neil Horowitz, MD
Support Research and Treatment at the Susan F. Smith Center
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: